Entering text into the input field will update the search result below

Puma Biotechnology continues to climb as analysts giddy over neratinib

Dec. 24, 2013 9:29 AM ETPuma Biotechnology, Inc. (PBYI) StockPBYIBy: Colin Lokey, SA News Editor1 Comment
  • Puma Biotechnology (NYSE:PBYI) jumps 5% before the bell on the heels of Monday night's neratinib call (see here).
  • Meanwhile, the sell-side is busy one-upping each other with price target hikes.
  • BofA is reportedly out lifting its price objective to $141. That looks like the third raise this month (see here and here).
  • Market chatter suggests Leerink's target is now $144.
  • Investors can probably expect more bullish calls to come.

Recommended For You

About PBYI Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
PBYI--
Puma Biotechnology, Inc.